CLSN - Celsion Corporation
Chart Events
Engulfing Line (Bullish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.8600 |
| Open | 2.9300 |
| Bid | 2.7800 x 1800 |
| Ask | 2.8400 x 3200 |
| Day's Range | 2.7600 - 2.9300 |
| 52 Week Range | 0.6900 - 3.6500 |
| Volume | 674,917 |
| Avg. Volume | 1,127,573 |
| Market Cap | 81.335M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4160 |
| Earnings Date | May 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
Fair Value
Related Research
- GlobeNewswire
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
Excellent Surgical Response Noted at the Higher, 100 mg/m2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When.
- GlobeNewswire
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J, May 15, 2020 -- Celsion.
- GlobeNewswire
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
Celsion Corporation (CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 15, 2020. To participate in the call, interested parties may dial 1-800-367-2403 (Toll-Free/North America) or 1-334-777-6978 (International/Toll) and ask for the Celsion Corporation First Quarter 2020 Earnings Call (Conference Code: 6901311) to register ten minutes before the call is scheduled to begin. An audio replay of the call will also be available on the Company's website, www.celsion.com, for 90 days after 2:00 p.m. EDT Friday, May 15, 2020.
- GlobeNewswire
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received $1.82 million of net cash proceeds from the sale of approximately $1.9 million of its unused New Jersey net operating losses (NOLs) and $632,220 in funding under the Paycheck Protection Program (PPP), the federal government's main initiative to help small businesses disrupted by the COVID-19 pandemic. The NOL sales cover the tax years 2017 and 2018 and are administered through the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) Program.
- Simply Wall St.
If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, Today
Celsion Corporation (NASDAQ:CLSN) shareholders will doubtless be very grateful to see the share price up 63% in the...
- GlobeNewswire
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (CLSN), an oncology drug-development company, announces that the prescribed minimum number of events of 158 patient deaths has been reached for the second pre-specified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the Independent Data Monitoring Committee (iDMC) is expected to meet in July to conduct the second interim analysis. Celsion expects to announce iDMC recommendations as soon as possible after the meeting.
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT
Q4 2019 Celsion Corp Earnings Call
- ACCESSWIRE
Celsion Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Celsion Corp. (NASDAQ:CLSN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM Eastern ...
- GlobeNewswire
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
Celsion Corporation (CLSN), a leading oncology drug development company, today jointly announced with Medidata, a Dassault Systèmes company, that examining matched patient data provided by Medidata in a synthetic control arm (SCA) with results from the Company’s completed Phase Ib dose-escalating OVATION I Study with GEN-1 in Stage III/IV ovarian cancer patients showed positive results in progression-free survival (PFS). The hazard ratio (HR) was 0.53 in the intent-to-treat (ITT) group, showing strong signals of efficacy.
- GlobeNewswire
Celsion Corporation Reports 2019 Financial Results and Provides Business Update
Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020.
- GlobeNewswire
Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency
Celsion Corporation (CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that GEN-1 be designated as an orphan medicinal product for the treatment of ovarian cancer. GEN-1, designed using Celsion's proprietary TheraPlas platform technology, is an interleukin-12 (IL-12) DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. GEN-1 previously received orphan designation from the U.S. Food and Drug Administration and is currently being evaluated in a Phase I/II clinical trial (the OVATION 2 Study) for the treatment of newly diagnosed patients with Stage III and IV ovarian cancer.
- GlobeNewswire
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 --.
- GlobeNewswire
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company to.
- GlobeNewswire
Celsion CEO Issues Letter to Stockholders
Celsion Corporation (CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following letter to stockholders. With the closing of a small equity fundraise today, Celsion has accomplished several important, positive objectives. First, we now count among our stockholders four institutional investors that have been following our progress with ThermoDox® over a sufficiently long period of time to fully understand our technology and the potential for success of our global Phase III OPTIMA Study in primary liver cancer, or HCC.
- GlobeNewswire
Celsion Corporation Prices $4.8 Million Registered Direct Offering
The Company has also agreed to issue to such investors, in a concurrent private placement, warrants to purchase 2,971,428 shares of the Company’s common stock. The gross proceeds of the offering will be approximately $4.8 million before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the offering for working capital and for other general corporate purposes.
- Simply Wall St.
When Can We Expect A Profit From Celsion Corporation (NASDAQ:CLSN)?
Celsion Corporation's (NASDAQ:CLSN): Celsion Corporation, a development stage oncology drug company, focuses on the...
- GlobeNewswire
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
Celsion Corporation (CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its initial safety review of data from the first fifteen patients treated with the first four neoadjuvant doses of GEN-1 at 100 mg/m² in the ongoing Phase I/II OVATION 2 Study. As requested by the U.S. Food and Drug Administration (FDA), a follow-on Phase 1 review by the DSMB will evaluate the safety of GEN-1 in up to 17 weekly doses before initiating the Phase 2 portion of the Study. The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy (NACT), a standard of care for newly diagnosed patients with Stage III and IV ovarian cancer.
- GlobeNewswire
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
Celsion Corporation (CLSN), an oncology drug-development company, announces that Prof. Riccardo Lencioni, M.D., FSIR, EBIR delivered a presentation titled “Thermally-Sensitive Ablation Enhancers: Where Do We Stand?” at the SPECTRUM 2020 Interventional Oncology Conference held in Miami , FLA last month. Dr. Lencioni is a professor in the Department of Radiology at the University of Pisa School of Medicine in Italy and is an Honorary Research Professor of Interventional Oncology at the Miami Cancer Institute.
- Simply Wall St.
Does Celsion Corporation (NASDAQ:CLSN) Have A High Beta?
If you're interested in Celsion Corporation (NASDAQ:CLSN), then you might want to consider its beta (a measure of...
- Zacks
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
- Zacks
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
- Zacks
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
- Zacks
Applied Therapeutics Up on Positive Galactosemia Study Data
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
- Zacks
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
- Zacks
aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma
aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.
